DUBLIN--(BUSINESS WIRE)--The "Global Vagus Nerve Stimulator Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2019 to 2027" report has been added to ResearchAndMarkets.com's offering.
The market growing at a CAGR of 7.4% during the forecast period from 2019 to 2027.
The global vagus nerve stimulator market is emerging efficiently from 2019 to 2027, accredited to increase in the minimally invasive surgical procedures along with enhanced vagus nerve stimulation therapies worldwide in the field of medical technology.
Globally, the U.S. generated maximum revenue in 2018. The top manufacturers in the U.S. continue to focus on R&D to innovate new applications along with external VNS Devices.
The increasing burden of a cerebral stroke and other neurological disorders, such as Parkinson's, and Alzheimer's leads to the increasing number of hospital admissions, which eventually upsurges the demand of neurosurgery devices. As per the statistics by American Neurological Association, neurological disorders impact more than 100 million U.S citizens every year, with the costs of medical expenditure for stroke and dementia alone estimated to total more than US$ 600 billion by 2030.
The major drivers are the increasing number of patients suffering with neurological & lifestyle disorders and swift adoption of the latest technology in the U.S market. For e.g. in 2017, the U.S. FDA approved marketing of "gammaCore" (handheld noninvasive vagus nerve stimulator/ (nVNS) therapy) manufactured by ElectroCore LLC, mainly for the preventive treatment of episodic cluster headaches.
Major clinical applications for epilepsy and depression will further spur revenue growth for implantable vagus nerve stimulators. Other treatment options include seizures, electroconvulsive therapy, pain, asthma, Crohn's disease, migraine, and other diseases.
However, reimbursement cuts, pricing pressures related to surgery, and complications after surgery and less technology expansion in the developing nations expected to temper revenue growth on a global scale.
Key Market Movements
- Globally, the vagus nerve stimulator is growing at a CAGR of 7.4% for the period from 2019 to 2027.
- The U.S. dominated the global market in 2018 on account of the rising number of minimally invasive surgeries, key players have concentrated on partnerships & product expansion, adoption of new techniques along with enhanced applications related to epilepsy and depression.
- The Asia Pacific market is projected to register the maximum growth rate during the forecast period due to the increasing population with growing neurological disorders, increased medical expenditure and technology expansion in countries such as Japan, India, China, South Korea, Australia, Singapore and Others.
- Major players in this vertical are Medtronic Plc., LivaNova Plc., BioControl Medical, EnteroMedics Inc., NERVANA LLC., ElectroCore LLC, Cerbomed GmbH, ReShape Lifesciences, Inc, Parasym Health, Innovative Health Solutions INC, Beijing PINS Medical Co., Ltd., Aleva Neurotherapeutics SA and others.
Key Topics Covered
Chapter 1. Preface
Chapter 2. Executive Summary
2.1. Global Vagus Nerve Stimulator Market Portraiture
2.2. Global Vagus Nerve Stimulator Market, By Product Type, 2018 (US$ Mn)
2.3. Global Vagus Nerve Stimulator Market, By Application, 2018 (US$ Mn)
2.4. Global Vagus Nerve Stimulator Market, By End User, 2018 (US$ Mn)
2.5. Global Vagus Nerve Stimulator Market, by Geography, 2018 vs. 2027 (Value %)
Chapter 3. Global Vagus Nerve Stimulator Market: Market Dynamics and Future Outlook
3.1. Market Overview
3.2. Vagus Nerve Stimulator Market Technologies: Future Trends
3.3. Current Scenario: New Product Launches, Technology Expansion
3.4. Challenges
3.5. Opportunities
3.6. Attractive Investment Proposition, by Geography, 2018
3.7. Competitive Landscape
3.7.1. Competitive Landscape, by Key Players, 2018
Chapter 4. Global Vagus Nerve Stimulator Market, by Product Type, 2017 - 2027 (US$ Mn)
4.1. Overview
4.2. Implantable Vagus Nerve Stimulator
4.3. Transcutaneous Vagus Nerve Stimulator (External)
Chapter 5. Global Vagus Nerve Stimulator Market, by Application, 2017 - 2027 (US$ Mn)
5.1. Overview
5.2. Pain Management
5.3. Depression & Anxiety
5.4. Epilepsy
5.5. Obesity
5.6. Others (Obstructive Sleep Apnea, Opoid Withdrawal)
Chapter 6. Global Vagus Nerve Stimulator Market, By End User, 2017 - 2027 (US$)
6.1. Overview
6.2. Hospitals
6.3. Specialty Clinics
6.4. Ambulatory Surgical Centers
Chapter 7. Global Vagus Nerve Stimulator Market, by Geography, 2017 - 2027 (US$ Mn)
7.1. Overview
7.2. North America Vagus Nerve Stimulator Market Analysis, 2017 - 2027
7.3. Europe Vagus Nerve Stimulator Market Analysis, 2017 - 2027
7.4. Asia Pacific Vagus Nerve Stimulator Market Analysis, 2017 - 2027
7.5. Latin America Vagus Nerve Stimulator Market Analysis, 2017 - 2027
7.6. Middle East & Africa (MEA) Vagus Nerve Stimulator Market Analysis, 2017 - 2027
Chapter 8. Company Profiles
8.1. Medtronic plc
8.1.1. Business Description
8.1.2. Financial InFormation (Subject to data availability)
8.1.3. Product Portfolio
8.1.4. Key Developments
8.2. LivaNova plc
8.3. BioControl Medical
8.4. EnteroMedics Inc.
8.5. NERVANA LLC
8.6. ElectroCore LLC
8.7. Cerbomed GmbH
8.8. ReShape Lifesciences Inc.
8.9. Parasym Health
8.10. Innovative Health Solutions Inc.
8.11. Beijing PINS Medical Co. Ltd.
8.12. Aleva Neurotherapeutics S.A.
For more information about this report visit https://www.researchandmarkets.com/r/s5k6m1
